The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.
We performed a multicenter survey using a semistructured interview in 1,072 consecutive patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to assess the prevalence of nonmotor symptoms (NMSs), their association with cognitive impairment, and the impact on patients' quality of life (QoL). We found that 98.6% of patients with PD reported the presence of NMSs. The most common were as follows: fatigue (58%), anxiety (56%), leg pain (38%), insomnia (37%), urgency and nocturia (35%), drooling of saliva and difficulties in maintaining concentration (31%). The mean number of NMS per patient was 7.8 (range, 0-32). NMS in the psychiatric domain were the most frequent (67%). Frequency of NMS increased along with the disease duration and severity. Patients with cognitive impairment reported more frequently apathy, attention/memory deficit, and psychiatric symptoms. Apathy was the symptom associated with worse PDQ-39 score but also presence of fatigue, attention/memory, and psychiatric symptoms had a negative impact on QoL. These findings further support a key role for NMS in the clinical frame of PD and the need to address them specifically in clinical trials using dedicated scales.
Barone
Paolo
P
Università Federico II and IDC-Hermitage-Capodimonte, Napoli, Italy.
Antonini
Angelo
A
Colosimo
Carlo
C
Marconi
Roberto
R
Morgante
Letterio
L
Avarello
Tania P
TP
Bottacchi
Eugenio
E
Cannas
Antonino
A
Ceravolo
Gabriella
G
Ceravolo
Roberto
R
Cicarelli
Giulio
G
Gaglio
Roberto M
RM
Giglia
Rosa M
RM
Iemolo
Francesco
F
Manfredi
Michela
M
Meco
Giuseppe
G
Nicoletti
Alessandra
A
Pederzoli
Massimo
M
Petrone
Alfredo
A
Pisani
Antonio
A
Pontieri
Francesco E
FE
Quatrale
Rocco
R
Ramat
Silvia
S
Scala
Rosanna
R
Volpe
Giuseppe
G
Zappulla
Salvatore
S
Bentivoglio
Anna Rita
AR
Stocchi
Fabrizio
F
Trianni
Giorgio
G
Dotto
Paolo Del
PD
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001007:Anxiety / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D003072:Cognition Disorders / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D003863:Depression / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D005221:Fatigue / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D005260:Female; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000857:Olfaction Disorders / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D010146:Pain / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D011788:Quality of Life; D020919:Sleep Disorders, Intrinsic / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D014555:Urination Disorders / Q000453:epidemiology / Q000209:etiology / Q000523:psychology
D000978:Antiparkinson Agents